COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps

Carcinogenesis

Volumn 32, Issue 9, 2011, Pages 1333-1339

  Nakanishi, Yuki ^a   Nakatsuji, Masato ^a   Seno, Hiroshi ^a   Ishizu, Shoko ^a   Akitake Kawano, Reiko ^a   Kanda, Keitaro ^a   Ueo, Taro ^a   Komekado, Hideyuki ^a   Kawada, Mayumi ^a   Minami, Manabu ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE POLYP; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 80052397157     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr128     Document Type: Article

References (43)

1. Mantovani, A. et al. (1992) The origin and function of tumor-associated macrophages. Immunol. Today, 13, 265-270.
2. Balkwill, F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
3. Gordon, S. et al. (2005) Monocyte and macrophage heterogeneity. Nat. Rev. Immunol., 5, 953-964.
4. Watkins, S.K. et al. (2007) IL-12 rapidly alters the functional profiles of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol., 178, 1357-1362.
5. Mantovani, A. et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol., 25, 677-686.
6. Mosmann, T.R. et al. (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine aactivities and secreted proteins. J. Immunol., 136, 2348-2357.
7. Mosser, D.M. et al. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol., 8, 958-969.
8. Sica, A. et al. (2008) Macrophage polarization in tumor progression. Semin. Cancer Biol., 18, 349-355.
9. Oshima, M. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
10. Chulada, P.C. et al. (2000) Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res., 60, 4705-4708.
11. Hull, M.A. et al. (1999) Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer, 79, 1399-1405.
12. Taketo, M.M. (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl Cancer Inst., 90, 1529-1536.
13. Taketo, M.M. (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl Cancer Inst., 90, 1609-1620.
14. Seno, H. et al. (2002) Cyclooxygenase-2 and prostaglandin E2 receptor EP2-dependent angiogenesis in Apc(delta716) mouse intestinal polyps. Cancer Res., 62, 506-511.
15. Bamba, H. et al. (1999) High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer, 83, 470-475.
16. Chapple, K.S. et al. (2000) Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol., 156, 545-553.
17. Hardwick, J.C. et al. (2001) NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene, 20, 819-827.
18. Hull, M.A. et al. (2006) Regulation of stromal cell cyclooxygenase 2 in the ApcMin/+ mouse model of intestinal tumorigenesis. Carcinogenesis, 27, 382-391.
19. Mantovani, A. et al. (2008) Cancer-related inflammation. Nature, 454, 436-444.
20. Steinbach, G. et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
21. Baron, J.A. et al. (2003) a randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348, 891-899.
22. Phillips, R.K. et al. (2002) A randomized, double blind, placebo controlled study of celocoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut, 50, 857-860.
23. Jacoby, R.F. et al. (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60, 5040-5044.
24. Dannenberg, A.J. et al. (2001) Cyclo-oxygenase2: a pharmacological target for the prevention of cancer. Lancet Oncol., 2, 544-551.
25. Gwyn, K. et al. (2002) Chemoprevention of colorectal cancer. Am. J. Gastroenterol., 97, 13-21.
26. Seno, H. et al. (2009) Efficient colonic mucosal wound repair requires Trem2 signaling. Proc. Natl Acad. Sci. USA, 106, 256-261.
27. Oshima, M. et al. (1995) Evidence against dominant negative mechanisms of intestinal polyp formation by Apc gene mutations. Cancer Res., 55, 2719-2722.
28. Popivanova, B.K. et al. (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest., 118, 560-570.
29. Swamy, M.V. et al. (2006) Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res., 66, 7370-7377.
30. Tjiu, J.W. et al. (2009) Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J. Invest. Dermatol., 129, 1016-1025.
31. Shankaran, V. et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumor immunogenicity. Nature, 410, 1107-1111.
32. Street, S.E. et al. (2002) Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med., 196, 129-134.
33. Duluc, D. et al. (2009) Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer, 125, 367-373.
34. Lewis, C.E. et al. (1999) Distinct role of macrophages in different tumor microenvironments. Cancer Res., 5, 1107-1113.
35. Mantovani, A. et al. (1986) Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim. Biophys. Acta, 865, 59-67.
36. Oguma, K. et al. (2008) Activated macrophages promote Wnt signaling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J., 27, 1671-1681.
37. Sica, A. et al. (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest., 117, 1155-1166.
38. Hagemann, T. et al. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kB. J. Exp. Med., 205, 1261-1268.
39. Bingle, L. et al. (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol., 196, 254-265.
40. Pollard, J.W. (2004) Tumor-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer, 4, 71-78.
41. Nakayama, Y. et al. (2002) Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res., 6C, 4291-4296.
42. Dunn, G.P. et al. (2006) Interferons, immunity and cancer immuoediting. Nat. Rev. Immunol., 11, 836-848.
43. Ostrand-Rosenberg, S. (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev., 18, 11-18.